Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial
Aim The aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one‐stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP). Materials and Methods Forty subjects were randomly allocated to two treatment groups....
Gespeichert in:
| Veröffentlicht in: | Journal of clinical periodontology Jg. 42; H. 2; S. 160 - 168 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Blackwell Publishing Ltd
01.02.2015
|
| Schlagworte: | |
| ISSN: | 0303-6979, 1600-051X, 1600-051X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Aim
The aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one‐stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP).
Materials and Methods
Forty subjects were randomly allocated to two treatment groups. The two treatment groups consisted of SRP combined with systemically admi‐nistered MOX at the dosage of 400 mg once daily for 7 days or SRP + placebo once daily for 7 days. Subgingival plaque samples were analysed for cultivable bacteria.
Results
Both groups resulted in significant reduction of probing depth (PD) and clinical attachment level (CAL) compared with baseline (p < 0.0001), and this difference was maintained at 6 months from baseline in both groups. However, subjects receiving MOX showed the greatest improvements CAL, and PD. Subjects in both groups at 6 months displayed the greatest reduction from baseline in frequency of sites with PD ≥6 mm (p < 0.001), favouring the MOX group. Adjunctive antibiotic protocol reduced subgingival Aggregatibacter actinomycetemcomitans to undetectable levels, after 3 and 6 months, and there was a significant reduction in the levels of Porphyromonas gingivalis and Tannerella forsythia in the MOX group compared to the placebo group.
Conclusions
The results from this study suggest that moxifloxacin as and adjunct to one‐stage full‐mouth SRP leads to a better clinical and microbiological advantages compared to mechanical treatment. |
|---|---|
| Bibliographie: | School of Dentistry of the Universidad de Antioquia, Medellín, Colombia - No. NCT02125812 ArticleID:JCPE12345 ark:/67375/WNG-RKWTRBZV-0 istex:5B95F2A19E2E96572A904DF7C57356D3522CC637 The authors declare that they have no conflict of interest in relation to this investigation. The School of Dentistry of the Universidad de Antioquia, Medellín, Colombia financed the study. Conflict of interest and source of funding statement ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ISSN: | 0303-6979 1600-051X 1600-051X |
| DOI: | 10.1111/jcpe.12345 |